132 related articles for article (PubMed ID: 38661491)
1. Corneal Complications Related to Dupilumab Use.
Tauber J; Ritterband DC; Kang JJ
Eye Contact Lens; 2024 Jun; 50(6):270-273. PubMed ID: 38661491
[TBL] [Abstract][Full Text] [Related]
2. Corneal Perforation in Patients Under Treatment With Dupilumab for Atopic Dermatitis.
Phylactou M; Jabbour S; Ahmad S; Vasquez-Perez A
Cornea; 2022 Aug; 41(8):981-985. PubMed ID: 34928552
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
Liberman P; Shifera AS; Berkenstock M
Cornea; 2020 Jun; 39(6):784-786. PubMed ID: 31985517
[TBL] [Abstract][Full Text] [Related]
4. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
[TBL] [Abstract][Full Text] [Related]
5. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
[TBL] [Abstract][Full Text] [Related]
6. Pathomechanism of dupilumab-associated inflammatory eye symptoms.
Wohlrab J; Werfel T; Wollenberg A
J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e435-e436. PubMed ID: 31220376
[No Abstract] [Full Text] [Related]
7. Conjunctivitis in dupilumab clinical trials.
Akinlade B; Guttman-Yassky E; de Bruin-Weller M; Simpson EL; Blauvelt A; Cork MJ; Prens E; Asbell P; Akpek E; Corren J; Bachert C; Hirano I; Weyne J; Korotzer A; Chen Z; Hultsch T; Zhu X; Davis JD; Mannent L; Hamilton JD; Teper A; Staudinger H; Rizova E; Pirozzi G; Graham NMH; Shumel B; Ardeleanu M; Wollenberg A
Br J Dermatol; 2019 Sep; 181(3):459-473. PubMed ID: 30851191
[TBL] [Abstract][Full Text] [Related]
8. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP
J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798
[TBL] [Abstract][Full Text] [Related]
9. Treatment of refractory conjunctivitis associated to dupilumab with topical pimecrolimus applied to the eyelid skin.
Sernicola A; Gattazzo I; Di Staso F; Giordano D; Capalbo A; Persechino F; Scuderi G; Persechino S
Dermatol Ther; 2019 Nov; 32(6):e13134. PubMed ID: 31639238
[TBL] [Abstract][Full Text] [Related]
10. [Ocular symptoms associated with dupilumab in atopic dermatitis].
Voorberg AN; Oosterhaven JAF; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30945835
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporine 0.1% (Ikervis
Roca-Ginés J; Rahhal-Ortuño M; Torres-Navarro I; Rodríguez-Serna M; Navarro-Mira MÁ
Arch Soc Esp Oftalmol (Engl Ed); 2019 Aug; 94(8):396-399. PubMed ID: 31178231
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab-Associated Ocular Surface Disease: Clinical Characteristics, Treatment, and Follow-Up.
Bohner A; Topham C; Strunck J; Haynes D; Brazil M; Clements J; Simpson E; Chamberlain W
Cornea; 2021 May; 40(5):584-589. PubMed ID: 32826648
[TBL] [Abstract][Full Text] [Related]
13. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
[TBL] [Abstract][Full Text] [Related]
14. Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis.
Yamane MLM; Belsito DV; Glass LRD
Orbit; 2019 Oct; 38(5):390-394. PubMed ID: 30628518
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study.
Schneeweiss MC; Kim SC; Wyss R; Schneeweiss S; Merola JF
J Am Acad Dermatol; 2021 Feb; 84(2):300-311. PubMed ID: 33038471
[TBL] [Abstract][Full Text] [Related]
16. Are serious ophthalmic adverse events on dupilumab treatment for atopic dermatitis dose related?
Mastorino L; Ortoncelli M; Avallone G; Quaglino P; Ribero S
Int J Dermatol; 2022 Oct; 61(10):e370-e372. PubMed ID: 34865213
[No Abstract] [Full Text] [Related]
17. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
Treister AD; Kraff-Cooper C; Lio PA
JAMA Dermatol; 2018 Oct; 154(10):1208-1211. PubMed ID: 30167653
[TBL] [Abstract][Full Text] [Related]
18. Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis.
Ivert LU; Wahlgren CF; Ivert L; Lundqvist M; Bradley M
Acta Derm Venereol; 2019 Apr; 99(4):375-378. PubMed ID: 30653240
[TBL] [Abstract][Full Text] [Related]
19. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Thaçi D; Deleuran M; Blauvelt A; Bissonnette R; de Bruin-Weller M; Hide M; Sher L; Hussain I; Chen Z; Khokhar FA; Beazley B; Ruddy M; Patel N; Graham NMH; Ardeleanu M; Shumel B
Am J Clin Dermatol; 2020 Aug; 21(4):567-577. PubMed ID: 32557382
[TBL] [Abstract][Full Text] [Related]
20. Uveitis and hypereosinophilia associated with dupilumab in an atopic dermatitis patient.
Zhang S; Lu L; Feng J; Hu Z; Song H; Yang L; Liu Y; Chen D; Wang T
J Dermatolog Treat; 2023 Dec; 34(1):2229466. PubMed ID: 37369546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]